*Seminar Series: IMB Chemistry and Structural Biology Division Seminar
*Location: Seminar Room 3.142, QBP Bldg 80, UQ St Lucia
*Date: 27/07/2017
*Time: 12:30

Speaker #1 details
*Title of talk: Potent, selective and oral CDK inhibitors for treating cancers
*Speaker's name: Professor Shudong Wang
*Speaker's organisation: University of South Australia
Speaker's city/state/country:
Talk Abstract: Cyclin-dependent kinases (CDKs) are deregulated in majority of cancers. The earlier generation of CDK inhibitors were non-specific, and toxicities have hampered their utilization. More recently, CDK4/6 inhibitors - palbociclib and ribociclib have received the regulatory approval for the treatment of metastatic breast cancer. This has fuelled significant research efforts to exploit CDKs for the development of the next generation of cancer therapies. In this talk, I will look at the identification of our drug candidates that target the individual CDK4, CDK6 and CDK9 for treating haematological cancer and solid tumour. I will discuss the drug target rationale, anti-cancer mechanisms, and preclinical drug development.
Speaker's bio: Professor Wang is Chair of Medicinal Chemistry and Head of the Centre for Drug Discovery & Development since 2012 at University of South Australia. Her research focuses on developing kinase targeted cancer therapies. Professor Wang spent 7 years in a British Biotech company (NASDAQGM: CYCC) working as a Head of Chemistry and oncology program manager. In 2005, she joined the University of Nottingham as Reader in Medicinal Chemistry at the School of Pharmacy. Her work in medicinal chemistry and drug development has led to several cancer drugs in clinical trials.

Speaker #2 details
*Title of talk:
*Speaker's name:
*Speaker's organisation:
Speaker's city/state/country:
Talk Abstract:
Speaker's bio:

Other Details:
*Host name: Professor David Fairlie
Host phone number:
*Host email: d.fairlie@imb.uq.edu.au